CortaGel

Ingredient matches for CortaGel

Hydrocortisone

Hydrocortisone is reported as an ingredient of CortaGel in the following countries:

• United States

International Drug Name Search

Falcol

Falcol may be available in the countries listed below.

Ingredient matches for Falcol

Aceclofenac

Aceclofenac is reported as an ingredient of Falcol in the following countries:

• Spain

International Drug Name Search

Isimig

Isimig may be available in the countries listed below.

Ingredient matches for Isimig

Frovatriptan

Frovatriptan succinate monohydrate (a derivative of Frovatriptan) is reported as an ingredient of Isimig in the following countries:

• France

International Drug Name Search

Ranitidine 50mg / 2ml Solution for Injection and Infusion

1. Name Of The Medicinal Product

Ranitidine 50mg/2ml Solution for Injection and Infusion

2. Qualitative And Quantitative Composition

Each one ml of solution contains 25mg ranitidine as ranitidine hydrochloride. Each 2ml ampoule contains 50mg ranitidine.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for Injection and Infusion

Clear, colourless solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Ranitidine Solution for Injection is indicated for the treatment of duodenal ulcer, benign gastric ulcer, post - operative ulcer, and of Zollinger - Ellison Syndrome.

In the management of conditions where reduction of gastric secretion and acid output is desirable, such as reflux oesphagitis.

As prophylaxis against:

• gastrointestinal haemorrhage from stress ulceration in seriously ill patients

• recurrent haemorrhage in patients with bleeding peptic ulcers

• acid aspiration (Mendelson's Syndrome) before anaesthesia in patients at risk, particularly obstetric patients during labour.

Children (6 months to 18 years)

• short term treatment of peptic ulcer

• treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.

4.2 Posology And Method Of Administration

For intravenous or intramuscular injection or, after dilution, for intravenous infusion. Whenever solution and container permit, parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration.

Adults (including elderly) and adolescents (12 years and older)

Ranitidine Solution for Injection may be given as:

• a slow intravenous injection (over at least two minutes) of 50 mg, after dilution to a volume of 20 ml per 50 mg dose. This dose may be repeated every six to eight hours

• an intermittent intravenous infusion at a rate of 25 mg per hour for two hours. The infusion may be repeated at six to eight hour intervals

• an intramuscular injection of 50 mg (2ml) every six to eight hours.

In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, parenteral administration may be continued until oral feeding commences. Patients considered to be still at risk may then be treated orally with tablets 150 mg twice daily.

In the prophylaxis of upper gastro-intestinal haemorrhage from stress ulceration in seriously ill patients a priming dose of 50 mg as a slow intravenous injection followed by a continuous intravenous infusion of 0.125 - 0.250 mg/kg/hr may be preferred.

In patients considered at risk of developing acid aspiration (Mendelson's) syndrome, Ranitidine Solution for Injection 50 mg may be given intramuscularly or by slow intravenous injection (over 2 minutes), 45 to 60 minutes before induction of general anaesthesia.

Children (6 months to 11 years)

See section 5.2 Pharmacokinetic Properties – Special Patient Populations

Ranitidine Injection may be given as a slow (over 2 minutes) i.v. injection up to a maximum of 50mg every 6 to 8 hours.

Peptic Ulcer Acute Treatment and Gastro-Oesophageal Reflux

Intravenous therapy in children with peptic ulcer disease is indicated only when oral therapy is not possible.

For acute treatment of peptic ulcer disease and gastro-oesophageal reflux in paediatric patients, Ranitidine injection may be administered at doses that have been shown to be effective for these diseases in adults and effective for acid suppression in critically ill children. The initial dose (2.0 mg/kg or 2.5 mg/kg, maximum 50 mg) may be administered as a slow intravenous infusion over 10 minutes, either with a syringe pump followed by a 3 ml flush with normal saline over 5 min, or following dilution with normal saline to 20 ml. Maintenance of pH> 4.0 can be achieved by intermittent infusion of 1.5 mg/kg every 6 h to 8 h. Alternatively treatment can be continuous, administering a loading dose of 0.45 mg/kg followed by a continuous infusion of 0.15 mg/kg/hr.

Prophylaxis of stress ulceration in seriously ill patients

The recommended dose for prophylaxis of stress ulceration is 1mg/kg (maximum 50 mg) every 6h to 8h.

Alternatively treatment can be continuous, administering 125 - 250 micrograms/kg/hr as continuous infusion.

Neonates (under 1 month)

See Section 5.2 Pharmacokinetic Properties – Special Patient Populations.

Renal Impairment

Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with severe renal impairment (creatinine clearance less than 50ml/min). It is recommended in such patients that Ranitidine Solution for Injection be administered in doses of 25mg.

4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients.

4.4 Special Warnings And Precautions For Use

Treatment with a histamine H₂-antagonist may mask the symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. Where gastric ulcer is suspected, the possibility of malignancy should be excluded before therapy with ranitidine is started.

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment. The dosage should be adjusted as detailed in Section 4.2 Posology and Method of Administration.

Asystole and bradycardia in association with rapid administration of ranitidine has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances. Recommended rates of administration should not be exceeded.

It has been reported that the use of higher than recommended doses of intravenous H₂-antagonists has been associated with rises in liver enzymes when treatment has been extended beyond five days.

Although clinical reports of acute intermittent porphyria associated with ranitidine administration have been rare and inconclusive, ranitidine should be avoided in patients with a history of this condition.

In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H₂ receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.63 (95% CI, 1.07–2.48).

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment

Interactions occur by several mechanisms including:

1) Inhibition of cytochrome P450-linked mixed function oxygenase system:

Ranitidine, at blood levels produced by standard doses, does not inhibit or interact significantly with the hepatic cytochrome P450-linked mixed function oxygenase system.

Accordingly, ranitidine in usual therapeutic doses, does not potentiate the actions of drugs which are inactivated by this enzyme; these include diazepam, lidocaine, phenytoin, propranolol and theophylline .

There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.

2) Competition for renal tubular secretion:

Since ranitidine is partially eliminated by the cationic system, it may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g. such as those used in the treatment of Zollinger-Ellison syndrome) may reduce the excretion of procainamide and N-acetylprocainamide resulting in increased plasma level of these drugs.

3) Alteration of gastric pH:

The bioavailability of certain drugs may be affected. This can result in either an increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitnib).

4.6 Pregnancy And Lactation

Ranitidine crosses the placenta but therapeutic doses administered to obstetric patients in labour or undergoing caesarean section have been without any adverse effect on labour, delivery or subsequent neonatal progress. Ranitidine is also excreted in human breast milk. Like other drugs, ranitidine should only be used during pregnancy or lactation if considered essential by a physician.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

The following convention has been utilised for the classification of undesirable effects: very common (

Blood & Lymphatic System Disorders

Unknown: Blood count changes (leucopenia, thrombocytopenia). These are usually reversible. Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or marrow aplasia.

Immune System Disorders

Uncommon: Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain).

Unknown: Anaphylactic shock

These events have been reported after a single dose.

Psychiatric Disorders

Very Rare: Depression.

Unknown: Reversible mental confusion and hallucinations.

These have been reported predominantly in severely ill and elderly patients.

Nervous System Disorders

Common: Headache (sometimes severe) and dizziness..

Unknown: Reversible involuntary movement disorders

Eye Disorders

Uncommon: Reversible blurred vision.

There have been reports of blurred vision, which is suggestive of a change in accommodation.

Cardiac Disorders

Unknown: As with other H₂ receptor antagonists bradycardia and A-V Block.

Vascular Disorders

Unknown: Vasculitis.

Gastrointestinal Disorders

Common: Diarrhoea.

Unknown: Acute pancreatitis.

Hepatobiliary Disorders

Very Rare: Transient and reversible changes in liver function tests.

Unknown: Hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice, these were usually reversible.

Skin and Subcutaneous Tissue Disorders

Uncommon: Skin Rash.

Unknown: Erythema multiforme, alopecia.

Musculoskeletal and Connective Tissue Disorders

Unknown: Musculoskeletal symptoms such as arthralgia and myalgia.

Renal and Urinary Disorders

Unknown: Acute interstitial nephritis.

Reproductive System and Breast Disorders

Unknown: Reversible impotence. Breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea).

The safety of ranitidine has been assessed in children aged 0 to 16 years with acid-related disease and was generally well tolerated with an adverse event profile resembling that in adults. There are limited long term safety data available, in particular regarding growth and development.

4.9 Overdose

Ranitidine is very specific in action and accordingly, no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. Ranitidine may be removed by haemodialysis.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: drugs for peptic ulcer and gastro-oesophageal reflux disease. H₂– receptor antagonist.

ATC code: A02B A02

Ranitidine is a specific, rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume, and the acid and pepsin content of the secretion.

The clinical data available mentions the use of ranitidine in children to prevent stress ulcers. No direct evidence for prevention of stress ulcers is available. Treatment for these patients is based on the observation that pH is below 4 after administration of ranitidine. The value of this surrogate parameter in children with stress ulcers remains to be established.

5.2 Pharmacokinetic Properties

Absorption of ranitidine after intramuscular injection is rapid and peak plasma concentrations are usually achieved within 15 minutes of administration. Ranitidine is not extensively metabolised. The elimination of the drug is primarily by tubular secretion. The elimination half-life of ranitidine is 2-3 hours. In studies with 150mg 3H-ranitidine, 93% of an intravenous dose was excreted in urine and 5% in faeces. Analysis of urine excreted in the first 24 hours after dosing showed that 70% of the intravenous dose was eliminated unchanged. About 6% of the dose is excreted in the urine as the N-oxide, 2% as desmethyl ranitidine and 1-2% as the furoic acid analogue.

Special Patient Populations

Children/infants (6 months and above)

Limited pharmacokinetic data show that there were no significant differences in half-life (range for children 3 years and above: 1.7 - 2.2 h) and plasma clearance (range for children 3 years and above: 9 - 22 ml/min/kg) between children and healthy adults receiving intravenous ranitidine when correction is made for body weight. Pharmacokinetic data in infants is extremely limited but appears to be in line with that for older children.

Neonates (under 1 month)

Limited pharmacokinetic data from term babies undergoing treatment with Extracorporeal Membrane Oxygenation (EMCO) suggests that plasma clearance following iv administration may be reduced (1.5-8.2 ml/min/kg) and the half-life increased in the new-born. Clearance of ranitidine appeared to be related to the estimated glomerular filtration rate in the neonates.

5.3 Preclinical Safety Data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Potassium dihydrogen phosphate

Disodium hydrogen phosphate dihydrate

Sodium chloride

Water for Injections

6.2 Incompatibilities

None

6.3 Shelf Life

2 years

6.4 Special Precautions For Storage

Do not store above 25°C. Keep ampoules in the outer carton in order to protect from light.

6.5 Nature And Contents Of Container

2 ml solution in amber, type 1 glass ampoules.

Pack size: 5 ampoules

6.6 Special Precautions For Disposal And Other Handling

Ranitidine Injection has been shown to be compatible with the following intravenous infusion fluids:

Sodium Chloride 0.9% w/v

Dextrose 5% w/v

Sodium Chloride 0.18% w/v and Dextrose 4% w/v

Sodium Bicarbonate 4.2% w/v

Hartmann's solution

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless preparation of solutions has taken place in controlled and validated aseptic conditions.

All solutions of Ranitidine Solution for Injection should be discarded after use.

7. Marketing Authorisation Holder

Beacon Pharmaceuticals Ltd

85 High Street

Tunbridge Wells

Kent TN1 1YG

UK

8. Marketing Authorisation Number(S)

PL 18157/0019

9. Date Of First Authorisation/Renewal Of The Authorisation

21 October 2008

10. Date Of Revision Of The Text

01 September 2010

Itaka

Itaka may be available in the countries listed below.

Ingredient matches for Itaka

Sildenafil

Sildenafil is reported as an ingredient of Itaka in the following countries:

• Venezuela

International Drug Name Search

Remestyp

Remestyp may be available in the countries listed below.

Ingredient matches for Remestyp

Terlipressin

Terlipressin is reported as an ingredient of Remestyp in the following countries:

• Bulgaria


• Czech Republic


• Poland


• Romania


• Slovakia

International Drug Name Search

Bronchialpastillen VA mit Codein

Bronchialpastillen VA mit Codein may be available in the countries listed below.

Ingredient matches for Bronchialpastillen VA mit Codein

Codeine

Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Bronchialpastillen VA mit Codein in the following countries:

• Switzerland

International Drug Name Search

Etoral Cream

Etoral Cream may be available in the countries listed below.

Ingredient matches for Etoral Cream

Ketoconazole

Ketoconazole is reported as an ingredient of Etoral Cream in the following countries:

• Vietnam

International Drug Name Search

Tetrin

Tetrin may be available in the countries listed below.

Ingredient matches for Tetrin

Tetracycline

Tetracycline complex with sodium metaphosphate (a derivative of Tetracycline) is reported as an ingredient of Tetrin in the following countries:

• Indonesia

International Drug Name Search

Minims Stains

Minims Stains may be available in the countries listed below.

Ingredient matches for Minims Stains

Fluorescein

Fluorescein sodium (a derivative of Fluorescein) is reported as an ingredient of Minims Stains in the following countries:

• Australia

International Drug Name Search

Efedrin SAD

Efedrin SAD may be available in the countries listed below.

Ingredient matches for Efedrin SAD

Ephedrine

Ephedrine hydrochloride (a derivative of Ephedrine) is reported as an ingredient of Efedrin SAD in the following countries:

• Denmark

International Drug Name Search

Ropinirol Orion

Ropinirol Orion may be available in the countries listed below.

Ingredient matches for Ropinirol Orion

Ropinirole

Ropinirole hydrochloride (a derivative of Ropinirole) is reported as an ingredient of Ropinirol Orion in the following countries:

• Slovakia

International Drug Name Search

Ismo Retard

Ismo Retard may be available in the countries listed below.

Ingredient matches for Ismo Retard

Isosorbide Mononitrate

Isosorbide Mononitrate is reported as an ingredient of Ismo Retard in the following countries:

• Sweden

International Drug Name Search

Isoniac

Isoniac may be available in the countries listed below.

Ingredient matches for Isoniac

Isoniazid

Isoniazid is reported as an ingredient of Isoniac in the following countries:

• Argentina

International Drug Name Search

Chemicetina

Chemicetina may be available in the countries listed below.

Ingredient matches for Chemicetina

Chloramphenicol

Chloramphenicol is reported as an ingredient of Chemicetina in the following countries:

• Italy

International Drug Name Search

Repaglinide

In the US, Repaglinide (repaglinide systemic) is a member of the drug class meglitinides and is used to treat Diabetes, Type 2.

US matches:

• Repaglinide


• Repaglinide/Metformin


• Repaglinide and metformin


• Repaglinide/Metformin Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A10BX02

CAS registry number (Chemical Abstracts Service)

0135062-02-1

Chemical Formula

C27-H36-N2-O4

Molecular Weight

452

Therapeutic Category

Oral antidiabetic agent, meglitinide (glinide)

Chemical Name

(+)-2-Ethoxy-α-[[(S)-α-isobutyl-o-piperidinobenzyl]carbamoyl]-p-toluic acid

Foreign Names

• Repaglinidum (Latin)
• Repaglinid (German)
• Répaglinide (French)
• Repaglinida (Spanish)

Generic Names

• Repaglinide (OS: BAN, USAN)
• Répaglinide (OS: DCF)
• AG-EE 623 ZW (IS)
• Repaglinide (PH: BP 2010, Ph. Eur. 6, USP 32)
• Repaglinidum (PH: Ph. Eur. 6)

Brand Names

• Dexanorm
  Dexa Medica, Indonesia



• Dianorm Rephco
  Rephco, Bangladesh



• Diarepa
  Techno, Bangladesh



• Enyglid
  TAD, Germany



• Glimet
  Drug International, Bangladesh



• Gluconorm
  Novo Nordisk, Canada



• Glukenil
  Lazar, Argentina



• Hipover
  Biopharm, Chile; Farmindustria, Peru



• Nomopil
  Incepta, Bangladesh



• Novade
  Eczacibasi, Turkey



• Novo Norm
  Novo Nordisk, Oman; Novo Nordisk, Romania



• NovoNorm
  Novo Nordisk, Argentina; Novo Nordisk, Austria; Novo Nordisk, Australia; Novo Nordisk, Bosnia & Herzegowina; Novo Nordisk, Belgium; Novo Nordisk, Bahrain; Novo Nordisk, Switzerland; Novo Nordisk, Chile; Novo Nordisk, China; Novo Nordisk, Cyprus; Novo Nordisk, Czech Republic; Novo Nordisk, Germany; Novo Nordisk, Denmark; Novo Nordisk, Egypt; Novo Nordisk, Spain; Novo Nordisk, Finland; Novo Nordisk, France; Novo Nordisk, Greece; Novo Nordisk, Hong Kong; Novo Nordisk, Croatia (Hrvatska); Novo Nordisk, Hungary; Novo Nordisk, Ireland; Novo Nordisk, Israel; Novo Nordisk, Iraq; Novo Nordisk, Iran; Novo Nordisk, Iceland; Novo Nordisk, Italy; Novo Nordisk, Jordan; Novo Nordisk, Kuwait; Novo Nordisk, Lebanon; Novo Nordisk, Luxembourg; Novo Nordisk, Myanmar; Novo Nordisk, Mexico; Novo Nordisk, Malaysia; Novo Nordisk, Netherlands; Novo Nordisk, Norway; Novo Nordisk, Peru; Novo Nordisk, Poland; Novo Nordisk, Qatar; Novo Nordisk, Serbia; Novo Nordisk, Russian Federation; Novo Nordisk, Saudi Arabia; Novo Nordisk, Sudan; Novo Nordisk, Sweden; Novo Nordisk, Singapore; Novo Nordisk, Slovenia; Novo Nordisk, Slovakia; Novo Nordisk, Syria; Novo Nordisk, Tunisia; Novo Nordisk, Turkey; Novo Nordisk, Taiwan; Novo Nordisk, Yemen; Novo Nordisk, South Africa



• Prandil
  Unimed & Unihealth, Bangladesh



• Prandin
  Daiichi Sankyo, United Kingdom; Menarini, Spain; Novo Nordisk, Luxembourg; Novo Nordisk, United States; Sanfer, Mexico



• Premil
  Beximco, Bangladesh; Beximco, Myanmar



• Rapilin
  Sun, India; Sun, Myanmar



• Regan
  Stancare, India



• Reglin
  General Pharma, Bangladesh



• Reodon
  Pliva, Croatia (Hrvatska)



• Repaglid
  Alco, Bangladesh



• Repaglind Stada
  Stada, Germany



• Repaglinid AbZ
  AbZ, Germany



• Repaglinid AL
  Aliud, Germany



• Repaglinid Hexal
  Hexal, Germany



• Repaglinid-CT
  CT Arzneimittel, Germany



• Repaglinid-ratiopharm
  Ratiopharm, Germany



• Sestrine
  Beta, Argentina



• Singlin
  Renata, Bangladesh



• Supernide
  Yu Sheng, Taiwan

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Talohexal

Talohexal may be available in the countries listed below.

Ingredient matches for Talohexal

Citalopram

Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Talohexal in the following countries:

• Australia

International Drug Name Search

Glizide

Glizide may be available in the countries listed below.

Ingredient matches for Glizide

Gliclazide

Gliclazide is reported as an ingredient of Glizide in the following countries:

• Myanmar


• Sri Lanka

International Drug Name Search

Tosidrin

Tosidrin may be available in the countries listed below.

Ingredient matches for Tosidrin

Dihydrocodeine

Dihydrocodeine tartrate (a derivative of Dihydrocodeine) is reported as an ingredient of Tosidrin in the following countries:

• Spain

International Drug Name Search

Livocab Nasal

Livocab Nasal may be available in the countries listed below.

Ingredient matches for Livocab Nasal

Levocabastine

Levocabastine hydrochloride (a derivative of Levocabastine) is reported as an ingredient of Livocab Nasal in the following countries:

• Spain

International Drug Name Search

Intragel

Intragel may be available in the countries listed below.

Ingredient matches for Intragel

Hyaluronic Acid

Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Intragel in the following countries:

• Turkey

International Drug Name Search

Alopurinol Teva

Alopurinol Teva may be available in the countries listed below.

Ingredient matches for Alopurinol Teva

Allopurinol

Allopurinol is reported as an ingredient of Alopurinol Teva in the following countries:

• Spain

International Drug Name Search

Edimox

Edimox may be available in the countries listed below.

Ingredient matches for Edimox

Acetazolamide

Acetazolamide is reported as an ingredient of Edimox in the following countries:

• Bangladesh

International Drug Name Search

Alfuzosin Sandoz

Alfuzosin Sandoz may be available in the countries listed below.

Ingredient matches for Alfuzosin Sandoz

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Alfuzosin Sandoz in the following countries:

• Denmark


• Germany


• Hungary


• Slovakia


• Switzerland

International Drug Name Search

Gabapentine CristerS

Gabapentine CristerS may be available in the countries listed below.

Ingredient matches for Gabapentine CristerS

Gabapentin

Gabapentin is reported as an ingredient of Gabapentine CristerS in the following countries:

• France

International Drug Name Search

Losartan Acostlabs

Losartan Acostlabs may be available in the countries listed below.

Ingredient matches for Losartan Acostlabs

Losartan

Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan Acostlabs in the following countries:

• Spain

International Drug Name Search

Pantoprazol Novafarm

Pantoprazol Novafarm may be available in the countries listed below.

Ingredient matches for Pantoprazol Novafarm

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol Novafarm in the following countries:

• Spain

International Drug Name Search

Fluvoxaminemaleaat Katwijk

Fluvoxaminemaleaat Katwijk may be available in the countries listed below.

Ingredient matches for Fluvoxaminemaleaat Katwijk

Fluvoxamine

Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Fluvoxaminemaleaat Katwijk in the following countries:

• Netherlands

International Drug Name Search

Flunixin N-Vet

Flunixin N-Vet may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Flunixin N-Vet

Flunixin

Flunixin meglumine (a derivative of Flunixin) is reported as an ingredient of Flunixin N-Vet in the following countries:

• Sweden

International Drug Name Search

Brivox

Brivox may be available in the countries listed below.

Ingredient matches for Brivox

Brivudine

Brivudine is reported as an ingredient of Brivox in the following countries:

• Costa Rica


• Dominican Republic


• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama

International Drug Name Search

Acetilcisteina

Acetilcisteina may be available in the countries listed below.

Ingredient matches for Acetilcisteina

Acetylcysteine

Acetilcisteina (DCIT) is known as Acetylcysteine in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Cremicort H1

Cremicort H1 may be available in the countries listed below.

Ingredient matches for Cremicort H1

Hydrocortisone

Hydrocortisone is reported as an ingredient of Cremicort H1 in the following countries:

• Luxembourg

International Drug Name Search

Flécaïnide Teva

Flécaïnide Teva may be available in the countries listed below.

Ingredient matches for Flécaïnide Teva

Flecainide

Flecainide acetate (a derivative of Flecainide) is reported as an ingredient of Flécaïnide Teva in the following countries:

• France

International Drug Name Search

Indometacine CF

Indometacine CF may be available in the countries listed below.

Ingredient matches for Indometacine CF

Indometacin

Indometacin is reported as an ingredient of Indometacine CF in the following countries:

• Netherlands

International Drug Name Search

Melorem

Melorem may be available in the countries listed below.

Ingredient matches for Melorem

Meloxicam

Meloxicam is reported as an ingredient of Melorem in the following countries:

• Greece

International Drug Name Search

Linkosol

Linkosol may be available in the countries listed below.

Ingredient matches for Linkosol

Lincomycin

Lincomycin is reported as an ingredient of Linkosol in the following countries:

• Turkey

International Drug Name Search

Axidexa

Axidexa may be available in the countries listed below.

Ingredient matches for Axidexa

Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Axidexa in the following countries:

• Germany

International Drug Name Search

Clotrimazolo EG

Clotrimazolo EG may be available in the countries listed below.

Ingredient matches for Clotrimazolo EG

Clotrimazole

Clotrimazole is reported as an ingredient of Clotrimazolo EG in the following countries:

• Italy

International Drug Name Search

Cytocristin

Cytocristin may be available in the countries listed below.

Ingredient matches for Cytocristin

Vincristine

Vincristine sulfate (a derivative of Vincristine) is reported as an ingredient of Cytocristin in the following countries:

• Bulgaria


• Latvia


• Vietnam

International Drug Name Search

Geniceral

Geniceral may be available in the countries listed below.

Ingredient matches for Geniceral

Idebenone

Idebenone is reported as an ingredient of Geniceral in the following countries:

• Argentina

International Drug Name Search

Clarute

Clarute may be available in the countries listed below.

Ingredient matches for Clarute

Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Clarute in the following countries:

• Japan

International Drug Name Search

Biocolchid

Biocolchid may be available in the countries listed below.

Ingredient matches for Biocolchid

Thiocolchicoside

Thiocolchicoside is reported as an ingredient of Biocolchid in the following countries:

• Venezuela

International Drug Name Search

Aldometil

Aldometil may be available in the countries listed below.

Ingredient matches for Aldometil

Methyldopa

Methyldopa is reported as an ingredient of Aldometil in the following countries:

• Austria

International Drug Name Search

Bal-Lanz

Bal-Lanz may be available in the countries listed below.

Ingredient matches for Bal-Lanz

Lansoprazole

Lansoprazole is reported as an ingredient of Bal-Lanz in the following countries:

• India

International Drug Name Search

Ciclavix

Ciclavix may be available in the countries listed below.

Ingredient matches for Ciclavix

Acyclovir

Aciclovir is reported as an ingredient of Ciclavix in the following countries:

• Brazil

International Drug Name Search

Kipres

Kipres may be available in the countries listed below.

Ingredient matches for Kipres

Montelukast

Montelukast sodium salt (a derivative of Montelukast) is reported as an ingredient of Kipres in the following countries:

• Japan

International Drug Name Search

Baklofen

Baklofen may be available in the countries listed below.

Ingredient matches for Baklofen

Baclofen

Baclofen is reported as an ingredient of Baklofen in the following countries:

• Norway

International Drug Name Search

Biotin beta

Biotin beta may be available in the countries listed below.

Ingredient matches for Biotin beta

Biotin

Biotin is reported as an ingredient of Biotin beta in the following countries:

• Germany

International Drug Name Search

Piracetam CF

Piracetam CF may be available in the countries listed below.

Ingredient matches for Piracetam CF

Piracetam

Piracetam is reported as an ingredient of Piracetam CF in the following countries:

• Netherlands

International Drug Name Search

Messelfenil

Messelfenil may be available in the countries listed below.

Ingredient matches for Messelfenil

Metamizole

Metamizole sodium anhydrous (a derivative of Metamizole) is reported as an ingredient of Messelfenil in the following countries:

• Mexico

International Drug Name Search

Claire

Claire may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Claire

Clenbuterol

Clenbuterol hydrochloride (a derivative of Clenbuterol) is reported as an ingredient of Claire in the following countries:

• Australia

International Drug Name Search

Xylose

In the US, Xylose is a member of the drug class miscellaneous uncategorized agents.

Ingredient matches for Xylose

Lactulose

Lactulose is reported as an ingredient of Xylose in the following countries:

• Bangladesh

International Drug Name Search

Cinedil

Cinedil may be available in the countries listed below.

Ingredient matches for Cinedil

Cinnarizine

Cinnarizine is reported as an ingredient of Cinedil in the following countries:

• Serbia

International Drug Name Search

Ratio-Indometacin

ratio-Indometacin may be available in the countries listed below.

Ingredient matches for ratio-Indometacin

Indometacin

Indometacin is reported as an ingredient of ratio-Indometacin in the following countries:

• Canada

International Drug Name Search

Caltrioject

Caltrioject may be available in the countries listed below.

Ingredient matches for Caltrioject

Calcitriol

Calcitriol is reported as an ingredient of Caltrioject in the following countries:

• Greece

International Drug Name Search

Histaloc

Histaloc may be available in the countries listed below.

Ingredient matches for Histaloc

Promethazine

Promethazine hydrochloride (a derivative of Promethazine) is reported as an ingredient of Histaloc in the following countries:

• Bahrain


• Oman

International Drug Name Search

Klopidogrel Arrow

Klopidogrel Arrow may be available in the countries listed below.

Ingredient matches for Klopidogrel Arrow

Clopidogrel

Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Klopidogrel Arrow in the following countries:

• Sweden

International Drug Name Search

Kind

Kind may be available in the countries listed below.

Ingredient matches for Kind

Levocetirizine

Levocetirizine is reported as an ingredient of Kind in the following countries:

• India

International Drug Name Search

Antox

Antox may be available in the countries listed below.

Ingredient matches for Antox

Ciprofloxacin

Ciprofloxacin is reported as an ingredient of Antox in the following countries:

• Costa Rica


• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama

International Drug Name Search

Hyso

Hyso may be available in the countries listed below.

Ingredient matches for Hyso

Scopolamine

Scopolamine is reported as an ingredient of Hyso in the following countries:

• Bangladesh

International Drug Name Search

Kenalgesic

Kenalgesic may be available in the countries listed below.

Ingredient matches for Kenalgesic

Ketorolac

Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Kenalgesic in the following countries:

• Colombia

International Drug Name Search

Ambroxol Sandoz

Ambroxol Sandoz may be available in the countries listed below.

Ingredient matches for Ambroxol Sandoz

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambroxol Sandoz in the following countries:

• Estonia


• Germany


• Italy


• Latvia


• Lithuania

International Drug Name Search

Cardiject

Cardiject may be available in the countries listed below.

Ingredient matches for Cardiject

Dobutamine

Dobutamine hydrochloride (a derivative of Dobutamine) is reported as an ingredient of Cardiject in the following countries:

• India


• Indonesia


• Myanmar


• South Africa

International Drug Name Search

Chloromycetin

In some countries, this medicine may only be approved for veterinary use.

In the US, Chloromycetin (chloramphenicol ophthalmic) is a member of the drug class miscellaneous antibiotics and is used to treat Anthrax, Bacterial Infection, Brucellosis, Cholera, Glanders, Meningitis, Ornithosis, Plague, Psittacosis, Rabbit Fever and Rickettsial Infection.

US matches:

• Chloromycetin Ophthalmic


• Chloromycetin Oral, Intravenous, Injection


• Chloromycetin Otic


• Chloromycetin Sodium Succinate


• Chloromycetin


• Chloromycetin Ophthalmic Ointment


• Chloromycetin Otic Solution

UK matches:

• Chloromycetin Ophthalmic Ointment (SPC)
• Chloromycetin Redidrops (SPC)

Ingredient matches for Chloromycetin

Chloramphenicol

Chloramphenicol is reported as an ingredient of Chloromycetin in the following countries:

• Argentina


• Australia


• Belize


• Chile


• Costa Rica


• El Salvador


• Finland


• Guatemala


• Honduras


• Iceland


• Ireland


• Japan


• Nicaragua


• Panama


• Peru


• South Africa


• Sweden


• United Kingdom


• United States

Chloramphenicol palmitate (a derivative of Chloramphenicol) is reported as an ingredient of Chloromycetin in the following countries:

• Belize


• Chile


• Costa Rica


• Ecuador


• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama


• Philippines

Chloramphenicol succinate sodium (a derivative of Chloramphenicol) is reported as an ingredient of Chloromycetin in the following countries:

• Argentina


• Hong Kong

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Paroxetine Topgen

Paroxetine Topgen may be available in the countries listed below.

Ingredient matches for Paroxetine Topgen

Paroxetine

Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetine Topgen in the following countries:

• Luxembourg

International Drug Name Search

Facicam

Facicam may be available in the countries listed below.

Ingredient matches for Facicam

Piroxicam

Piroxicam is reported as an ingredient of Facicam in the following countries:

• Dominican Republic


• Guatemala


• Mexico

International Drug Name Search

Ephedrine HCl Berlico

Ephedrine HCl Berlico may be available in the countries listed below.

Ingredient matches for Ephedrine HCl Berlico

Ephedrine

Ephedrine hydrochloride (a derivative of Ephedrine) is reported as an ingredient of Ephedrine HCl Berlico in the following countries:

• Indonesia

International Drug Name Search

Cognex

In the US, Cognex (tacrine systemic) is a member of the drug class cholinesterase inhibitors and is used to treat Alzheimer's Disease.

US matches:

• Cognex

Ingredient matches for Cognex

Tacrine

Tacrine hydrochloride (a derivative of Tacrine) is reported as an ingredient of Cognex in the following countries:

• Chile


• Greece


• United States

International Drug Name Search

Laurimic

Laurimic may be available in the countries listed below.

Ingredient matches for Laurimic

Fenticonazole

Fenticonazole nitrate (a derivative of Fenticonazole) is reported as an ingredient of Laurimic in the following countries:

• Spain

International Drug Name Search

Flutazolam

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0027060-91-9

Chemical Formula

C19-H18-Cl-F-N2-O3

Molecular Weight

376

Therapeutic Categories

Anxiolytic agent

Sedative agent

Benzodiazepine derivative

Chemical Name

Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)-

Foreign Names

• Flutazolamum (Latin)
• Flutazolam (German)
• Flutazolam (French)
• Flutazolam (Spanish)

Generic Names

• Flutazolam (OS: JAN)
• MS 4101 (IS)

Brand Name

• Coreminal
  Sawai Seiyaku, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Flutiamik

Flutiamik may be available in the countries listed below.

Ingredient matches for Flutiamik

Finasteride

Finasteride is reported as an ingredient of Flutiamik in the following countries:

• Argentina

International Drug Name Search

Caloidal

Caloidal may be available in the countries listed below.

Ingredient matches for Caloidal

Calcium

Calcium is reported as an ingredient of Caloidal in the following countries:

• Peru

International Drug Name Search

Benzyl Nicotinate

Benzyl Nicotinate may be available in the countries listed below.

Ingredient matches for Benzyl Nicotinate

Nicotinic Acid

Benzyl Nicotinate (JAN) is also known as Nicotinic Acid (Rec.INN)

International Drug Name Search

Glossary

JAN	Japanese Accepted Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Gabax

Gabax may be available in the countries listed below.

Ingredient matches for Gabax

Gabapentin

Gabapentin is reported as an ingredient of Gabax in the following countries:

• Germany


• Poland

International Drug Name Search

Rozex Cream

1. Name Of The Medicinal Product

Rozex Cream

2. Qualitative And Quantitative Composition

Metronidazole Ph. Eur 0.75% w/w

3. Pharmaceutical Form

Cream

4. Clinical Particulars

4.1 Therapeutic Indications

Indicated in the treatment of inflammatory papules, pustules and erythema of rosacea

4.2 Posology And Method Of Administration

For topical administration only.

The average period of treatment is three to four months. The recommended duration of treatment should not be exceeded. However, if a clear benefit has been demonstrated, continued therapy for a further three to four months period may be considered by the prescribing physician depending on the severity of the condition. In clinical studies, topical metronidazole therapy for rosacea has been continued for up to 2 years. In the absence of a clear clinical improvement, therapy should be stopped.

Adults: Rozex Cream should be applied in a thin layer to the affected areas of the skin twice daily, morning and evening. Areas to be treated should be washed with a mild cleanser before application. Patients may use non-comedogenic and non-astringent cosmetics after application of Rozex Cream.

Elderly: The dosage recommended in the elderly is the same as that recommended in adults.

Children: Not recommended. Safety and efficacy have not been established.

4.3 Contraindications

Contraindicated in individuals with a history of hypersensitivity to Metronidazole, or other ingredients of the formulation.

4.4 Special Warnings And Precautions For Use

Contact with mucous membranes should be avoided.

Rozex Cream has been reported to cause lacrimation of the eyes, therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs patients should be directed to use the medication less frequently or discontinue use temporarily and to seek medical advice if necessary. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of, blood dyscrasia. Exposure of treated sites to ultraviolet (e.g. solarium, sun-lamp) or strong sunlight (including sun-bathing) should be avoided during use of metronidazole. Unnecessary and prolonged use of this medication should be avoided.

Evidence suggests that metronidazole is carcinogenic in certain animal species. There is no evidence to date of a carcinogenic effect in human (see section 5.3).

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Interaction with systemic medication is unlikely because absorption of metronidazole following cutaneous application of Rozex Cream is low. Nevertheless, it should be mentioned that disulfiram-like reactions have been reported in a small number of patients taking metronidazole and alcohol concomitantly. Oral metronidazole has been reported to potentiate the effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin is not known. However, very rare cases of modification of the INR values have been reported with concomitant use of Rozex and coumarin anticoagulants.

4.6 Pregnancy And Lactation

There is no experience to date with the use of Rozex Cream in pregnancy. In case of oral administration, metronidazole crosses the placental barrier and rapidly enters the foetal circulation. No foetotoxicity was observed after oral metronidazole in either rats or mice. However because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents this drug should be used in pregnancy only if clearly needed.

After oral administration, Metronidazole is excreted in breast milk in concentrations similar to those found in the plasma. Even though Metronidazole blood levels from topical administration are significantly lower than those achieved after oral administration, in nursing mothers a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

4.7 Effects On Ability To Drive And Use Machines

Based upon the pharmacodynamic profile and clinical experience performance related to driving and using machines should not be affected.

4.8 Undesirable Effects

Because of the minimal absorption of metronidazole and consequently its insignificant plasma concentration after topical administration, the adverse experiences reported with the oral form of the drug have not been reported with Rozex Cream. Adverse reactions reported with Rozex Cream have been only local and mild.

The following spontaneous adverse experiences have been reported, and within each system organ class, are ranked by frequency, using the following convention:

Very common (

Common (

Uncommon (

Rare (

Very rare (<1/10,000), including isolated reports

Skin and subcutaneous tissue disorders:

Common: dry skin, erythema, pruritus, skin discomfort (burning, pain of skin/stinging), skin irritation, worsening of rosacea.

Unknown frequency: contact dermatitis

Nervous System disorders:

Uncommon: hypothesia, paraesthesia, dysgeusia (metallic taste)

Gastrointestinal disorders:

Uncommon: nausea

Watery eyes have been reported if applied too closely to this area.

4.9 Overdose

No data exists about overdosage in humans. Acute oral toxicity studies with a topical gel formulation containing 0.75% w/w metronidazole in rats have shown no toxic action with doses of up to 5 g of finished product per kilogram body weight, the highest dose used. This dose is equivalent to the oral intake of 12 tubes of 30g packaging Rozex Cream for an adult weighing 72 kg, and 2 tubes of Cream for a child weighing 12 kg.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Metronidazole is an antiprotozoal and antibacterial agent which is active against a wide range of pathogenic micro-organisms. The mechanisms of action of metronidazole in rosacea are unknown but available evidence suggests that the effects may be antibacterial and/or anti-inflammatory.

5.2 Pharmacokinetic Properties

Metronidazole is rapidly and nearly totally absorbed after oral administration. The drug is not significantly bound to serum proteins and distributes well to all body compartments with the lowest concentration found in the fat. Metronidazole is excreted primarily in the urine as parent drug, oxidative metabolites and conjugates.

Bioavailability studies with a topical 1g application of Rozex Cream to the face of normal subjects resulted in mean maximum serum concentrations of 32.9ng/ml (range 14.8 to 54.4ng/ml) which is approximately 100 times less than those attained after a single oral dose of 250 mg (mean Cmax = 7248ng/ml; range 4270 – 13970ng/ml). The peak concentration occurred between 0.25 – 4 hours after oral dosing, and 6 to 24 hours after cutaneous application of Rozex Cream.

Following topical application of Rozex Cream, serum concentrations of the major metabolite (the hydroxymetabolite 2-hydroxymethylmetronidazole) were below the quantifiable limit of the assay (<9.6ng/ml) at most of the time points, ranging to a maximum of 17.5ng/ml peak concentration between 8 and 24 hours after application. In comparison, the peak concentration following a 250mg oral dose ranged from 626 to 1788ng/ml between 4 and 12 hours after dosing.

The extent of exposure (Area under the curve, AUC) from a 1g application of metronidazole administered topically was 1.36% of the AUC of a single oral 250mg metronidazole dose (mean + 912.7ng.hr/ml and approximately 67207ng.ml/hr respectively).

5.3 Preclinical Safety Data

No evidence for a primary dermal irritation was observed in rabbits following a single 24-hour cutaneous application of Rozex Cream to abraded and non-abraded skin, under occlusion.

Metronidazole has shown mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injection and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200 to 1200mg/day of oral metronidazole for 1 to 24 months. However, the preponderance of evidence from these studies suggests that although metronidazole has a potential for producing mutations, this should not occur in well oxygenated mammalian cells, i.e., under normal aerobic conditions.

The carcinogenicity of metronidazole by the oral route of administration has been evaluated in rats, mice and hamsters. These studies showed that oral metronidazole caused an increased incidence of pulmonary tumours in mice and possibly other tumours, including liver tumours, in the rat. Conversely, two lifetime studies in hamsters produced negative results. Moreover, one study showed a significant enhancement of UV-induced skin tumours in hairless mice treated with metronidazole intraperitoneally (15μg per g body weight and per day for 28 weeks).

Although the significance of these results to the cutaneous use of metronidazole for the treatment of rosacea is unclear, patients should be advised to avoid or minimise exposure of metronidazole cream-treated sites to sun. After several decades of systemic use, no evidence has been published to suggest that metronidazole is associated with carcinogenic potential in humans.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Emulsifying Wax, Benzyl alcohol, Isopropyl palmitate, Glycerol, Sorbitol 70% (non-crystallising), lactic acid and/or Sodium Hydroxide, Purified Water.

6.2 Incompatibilities

None known

6.3 Shelf Life

Rozex Cream has a shelf life when unopened of 36 months

6.4 Special Precautions For Storage

Store at a temperature not exceeding 25°C. Do not refrigerate.

6.5 Nature And Contents Of Container

Aluminium tubes with epoxy phenolic lining, fitted with white polypropylene screw caps; pack sizes: 30g, 40g & 50g

6.6 Special Precautions For Disposal And Other Handling

Replace cap tightly after use.

7. Marketing Authorisation Holder

Galderma (UK.) Limited

Meridien House

69-71 Clarendon Road

Watford

Herts.

WD17 1DS

UK

8. Marketing Authorisation Number(S)

PL 10590/0028

9. Date Of First Authorisation/Renewal Of The Authorisation

18^th June 1997

10. Date Of Revision Of The Text

December 2010

Clorotrimeton

Clorotrimeton may be available in the countries listed below.

Ingredient matches for Clorotrimeton

Chlorphenamine

Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Clorotrimeton in the following countries:

• Colombia


• Venezuela

International Drug Name Search

Alenstran

Alenstran may be available in the countries listed below.

Ingredient matches for Alenstran

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Alenstran in the following countries:

• Greece

International Drug Name Search

Planak

Planak may be available in the countries listed below.

Ingredient matches for Planak

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Planak in the following countries:

• Indonesia

Levonorgestrel

Levonorgestrel is reported as an ingredient of Planak in the following countries:

• Indonesia

International Drug Name Search

Antitrombina III Grifols

Antitrombina III Grifols may be available in the countries listed below.

Ingredient matches for Antitrombina III Grifols

Antithrombin Iii

Antithrombin III is reported as an ingredient of Antitrombina III Grifols in the following countries:

• Argentina


• Chile

International Drug Name Search

Galpseud

Galpseud may be available in the countries listed below.

Ingredient matches for Galpseud

Chlorphenamine

Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Galpseud in the following countries:

• United Kingdom

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Galpseud in the following countries:

• United Kingdom

International Drug Name Search

Loperamid-Akri

Loperamid-Akri may be available in the countries listed below.

Ingredient matches for Loperamid-Akri

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Loperamid-Akri in the following countries:

• Russian Federation

International Drug Name Search

Allegron

Allegron may be available in the countries listed below.

UK matches:

• ALLEGRON (King Pharmaceuticals Ltd) (SPC)

Ingredient matches for Allegron

Nortriptyline

Nortriptyline hydrochloride (a derivative of Nortriptyline) is reported as an ingredient of Allegron in the following countries:

• Australia


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Tétrazépam Almus

Tétrazépam Almus may be available in the countries listed below.

Ingredient matches for Tétrazépam Almus

Tetrazepam

Tetrazepam is reported as an ingredient of Tétrazépam Almus in the following countries:

• France

International Drug Name Search

Coopersect

Coopersect may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Coopersect

Deltamethrin

Deltamethrin is reported as an ingredient of Coopersect in the following countries:

• Finland


• Norway

International Drug Name Search

Macrolid

Macrolid may be available in the countries listed below.

Ingredient matches for Macrolid

Roxithromycin

Roxithromycin is reported as an ingredient of Macrolid in the following countries:

• Greece

International Drug Name Search

Intralipid

In the US, Intralipid (fat emulsion systemic) is a member of the drug class intravenous nutritional products.

US matches:

• Intralipid

Ingredient matches for Intralipid

Soya-bean oil

Soya-bean oil is reported as an ingredient of Intralipid in the following countries:

• Australia


• Switzerland


• Turkey

International Drug Name Search

Humacarpin

Humacarpin may be available in the countries listed below.

Ingredient matches for Humacarpin

Pilocarpine

Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Humacarpin in the following countries:

• Hungary

International Drug Name Search

Bestafen

Bestafen may be available in the countries listed below.

Ingredient matches for Bestafen

Ibuprofen

Ibuprofen is reported as an ingredient of Bestafen in the following countries:

• Mexico

International Drug Name Search

Findedol Max

Findedol Max may be available in the countries listed below.

Ingredient matches for Findedol Max

Chondroitin Polysulfate

Chondroitin Polysulfate is reported as an ingredient of Findedol Max in the following countries:

• Peru

Glucosamine

Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Findedol Max in the following countries:

• Peru

International Drug Name Search

Flogofin

Flogofin may be available in the countries listed below.

Ingredient matches for Flogofin

Ketoprofen

Ketoprofen is reported as an ingredient of Flogofin in the following countries:

• Chile

International Drug Name Search